Pharma News
This Week
May 30, 2025
Eli Lilly: A Rising Biotech Leader with Growth Potential - TradingView
Eli Lilly (LLY) is emerging as a growth leader in Big Pharma, driven by blockbuster drugs Mounjaro and Zepbound, which generated $3.84 billion and $2.31 billion, respectively, in Q1 2025. With a strong pipeline including Orforglipron and Donanemab, and over $50 billion invested in U.S. manufacturing, Lilly is positioned for long-term success and stability.
May 29, 2025
BOCOMI: Numerous Chinese Innovative Pharmaceuticals Set to Reveal Major Findings at ASCO Conference
SINO BIOPHARM and CSPC PHARMA saw significant stock increases, with SINO BIOPHARM rising 5.5% to $4.42 and CSPC PHARMA surging 11.6% following the announcement of its first-quarter results. The ASCO meeting is expected to showcase many innovative Chinese drugs, highlighting a record number of selected candidates.
May 29, 2025
HK inno.N receives phase 3 approval for canine eczema treatment, competing with Zoetis' Apoquel - KBR
HK inno.N has received approval to begin a phase 3 trial for its next-gen JAK1 inhibitor, IN-115314, aimed at treating atopic dermatitis in dogs. The trial will directly compare IN-115314 to Zoetis’ established drug, Apoquel (oclacitinib). IN-115314 is designed for greater selectivity and fewer side effects, potentially revolutionizing pet pharmaceuticals, similar to HK inno.N's success with K-CAB.
May 29, 2025
Morgan Lewis Presents the 27th Edition of Blockbuster Biologics Review
The latest issue of Blockbuster Biologics Review discusses post-grant challenges and patent litigations affecting blockbuster biologics, revealing a 58% institution rate for inter partes review challenges. It also notes 74 US biosimilar approvals, including Jobevne and Merilog, and highlights bipartisan legislative efforts on drug patents and pricing, alongside FDA's new research roadmap for biosimilars.
May 29, 2025
3SBio secures major $6 billion agreement for cancer medication - Insights for global investors on China's stock market
Pfizer has acquired international rights to the experimental cancer therapy SSGJ-707 from China's 3SBio Inc. for an initial $1.25 billion, with potential milestone payments of up to $4.8 billion. This deal marks a significant milestone for China's biopharma sector, driving 3SBio's stock to a seven-year high. The bispecific antibody targets PD-1 and VEGF pathways to combat lung and other cancers.
May 29, 2025
Eisai and Merck successfully fend off generic rivals for their popular cancer medication, Lenvima.
May 29, 2025
AbbVie Shares Decline Approximately 13% Over the Past Three Months: Is It a Good Time to Invest? - TradingView
AbbVie (ABBV) stock has declined 12.6% over the past three months amid macroeconomic uncertainty and tariff concerns. Despite losing patent protection for Humira, AbbVie’s new drugs, Skyrizi and Rinvoq, generated $5.1 billion in Q1 2025. The company anticipates robust growth driven by these products and a strong pipeline, while facing challenges in aesthetics sales and Humira erosion.
May 29, 2025
Weight-loss clinic responds to claims made by Novo Nordisk regarding Ozempic TM | Americas
Novo Nordisk is encountering pushback from a Connecticut clinic over the use of its drugs Ozempic and Wegovy. The clinic asserts that its compounded semaglutide practices were lawful and transparent to patients. LIVation has acknowledged referencing Novo Nordisk products in previous marketing, which has since been retracted.
May 28, 2025
Eisai and Merck Successfully Maintain Lenvima Patent Against Shilpa's Challenge - Bloomberg Law
Eisai Co. Ltd. and Merck & Co. successfully defended their patent for the cancer drug Lenvima against Shilpa Medicare Ltd.'s challenge. A federal judge ruled that the patent, which covers the active ingredient lenvatinib mesylate, is valid, potentially blocking Shilpa's generic versions for another decade.
May 28, 2025
Ozempic: Understanding the science of this groundbreaking medication and its unexplored possibilities - Tiny Matters
The FDA approved semaglutide, marketed as Ozempic, in December 2017 for type 2 diabetes, followed by Wegovy for chronic weight management. Users report significant weight loss, making Ozempic a blockbuster drug. While these medications show promise for various health issues, including Alzheimer’s and addiction, they also carry potential risks.
May 28, 2025
Ex-FDA chief warns that budget reductions could jeopardize one of Trump's significant accomplishments in drug pricing.
The FDA's recent disbandment of its Division of Policy Development threatens the progress made in approving affordable generic drugs, including complex medications like GLP-1 treatments. This team, responsible for crucial policy guidance, was instrumental in achieving record generic drug approvals during Trump's presidency, yielding $26 billion in savings. The cuts could stall competition and price reductions in the drug market.
May 28, 2025
Globalpharma develops alternatives to Ozempic | AGBI
Globalpharma, a UAE drugmaker, is preparing to manufacture generic versions of Ozempic and other GLP-1 therapies, targeting diabetes and obesity treatment. The company is exploring partnerships to develop peptide-based injectables using off-patent precursors. With plans to localize production, Globalpharma aims to meet rising demand and enhance access to these medications in the region.
May 27, 2025
Federal Circuit declines to pause Novartis dispute with MSN regarding Entresto | Americas
Novartis is seeking an injunction to prevent a generic version of its heart treatment, Entresto, from entering the market after the Court of Appeals denied a rehearing on the patent issue. MSN argues that the Entresto patent should be removed from the Orange Book, intensifying the legal battle over the drug's exclusivity.
May 27, 2025
Novo Nordisk is set to introduce its highly anticipated obesity medication, Wegovy, in India shortly, according to sources.
Danish drugmaker Novo Nordisk A/S is set to launch its weight-loss drug Wegovy (semaglutide) in India soon, addressing the growing obesity crisis. The launch follows delays due to high global demand and aims to compete with Eli Lilly's Mounjaro. With semaglutide's patent expiring in March 2026, Novo is racing against time to capture market share.
May 27, 2025
Federal Trade Commission Pursues Actions to Remove Patents from Drug Device Administration in ...
The FTC continues its crackdown on Orange Book-listed device patents, sending warning letters to Novartis, Mylan, Teva, Amphastar, and Covis. This follows a Federal Circuit ruling in Teva Pharms. Inc. v. Amneal Pharms. LLC, supporting the FTC's stance. Despite changes in administration, the FTC's focus on patent propriety remains consistent, highlighting bipartisan concerns over drug pricing.
May 27, 2025
Advancements in Drug Development in Microgravity: A New Era for Biopharmaceutical Innovation | ITIF
Microgravity research aboard the International Space Station (ISS) is revolutionizing drug development, enabling better protein crystallization and advanced tissue studies. Companies like Merck are exploring microgravity's potential to enhance cancer drug Keytruda® (pembrolizumab). As public and private sectors invest in this field, policymakers are urged to support regulatory frameworks and funding to accelerate biopharmaceutical innovation in space.
May 27, 2025
AZN Receives CHMP Approval for Imfinzi in Treating Muscle-Invasive Bladder Cancer - TradingView
AstraZeneca's cancer drug Imfinzi (durvalumab) received a positive opinion from the European Medicines Agency's CHMP for treating muscle-invasive bladder cancer in combination with gemcitabine and cisplatin. This follows FDA approval for a similar indication. Imfinzi is a key revenue driver for AstraZeneca, generating $1.26 billion in Q1 2025, with ongoing studies for further indications.
May 26, 2025
The post-antibiotic age has arrived, and low- and middle-income countries must not be overlooked.
Antimicrobial resistance (AMR) poses a severe health threat in low- and middle-income countries (LMICs), causing 4.3 million deaths annually. Pharmaceutical companies like Sanofi and Shionogi are addressing this by enhancing local production and access to antibiotics. Initiatives such as Pfizer's "Accord for a Healthier World" aim to provide essential medicines in LMICs, highlighting the urgent need for collaboration to combat AMR.
May 26, 2025
FTC Reinstates Efforts to Address Incorrect Patent Listings in Order to Tackle Elevated Drug Costs
The FTC has intensified its crackdown on improper patent listings by major pharmaceutical companies, including Novartis, Amphastar Pharmaceuticals, Mylan Specialty, Covis Pharma, and Teva. The agency issued warning letters regarding over 200 questionable patents that hinder generic competition and inflate drug prices. Companies have 30 days to amend or withdraw these listings, aiming to enhance market competition and reduce costs for consumers.
May 26, 2025
GILD Reports Encouraging Results for Trodelvy in Initial Treatment of Breast Cancer - TradingView
Gilead Sciences, Inc. (GILD) announced positive results from the phase III ASCENT-03 study for its breast cancer drug, Trodelvy (sacituzumab govitecan-hziy), showing significant improvement in progression-free survival for first-line metastatic triple-negative breast cancer patients. This follows another successful study, ASCENT-04. Gilead's shares have risen 17.1% this year, bolstered by Trodelvy's potential as a key treatment option.
